1. Home
  2. KITT vs LABT Comparison

KITT vs LABT Comparison

Compare KITT & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nauticus Robotics Inc.

KITT

Nauticus Robotics Inc.

HOLD

Current Price

$1.38

Market Cap

2.4M

Sector

Industrials

ML Signal

HOLD

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

HOLD

Current Price

$0.74

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KITT
LABT
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.2M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
KITT
LABT
Price
$1.38
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
460.4K
★ 531.9K
Earning Date
11-13-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.55
N/A
EPS
★ N/A
N/A
Revenue
★ $11,434,959.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 33.10
N/A
52 Week Low
$0.39
$0.73
52 Week High
$3.51
$6.85

Technical Indicators

Market Signals
Indicator
KITT
LABT
Relative Strength Index (RSI) 54.62 25.38
Support Level $0.63 N/A
Resistance Level $2.08 $2.13
Average True Range (ATR) 0.24 0.17
MACD -0.00 -0.04
Stochastic Oscillator 32.93 0.26

Price Performance

Historical Comparison
KITT
LABT

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: